ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00807495
Recruitment Status : Completed
First Posted : December 12, 2008
Results First Posted : March 27, 2018
Last Update Posted : March 27, 2018
Sponsor:
Information provided by (Responsible Party):
Takeda ( Millennium Pharmaceuticals, Inc. )

December 11, 2008
December 12, 2008
January 4, 2018
March 27, 2018
March 27, 2018
February 10, 2009
January 4, 2011   (Final data collection date for primary outcome measure)
Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria) [ Time Frame: Baseline and every 2 cycles up to Month 12 (approximately 16 cycles), from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months from last dose (Up to 4 years) ]
Best overall response rate is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the Investigator using International Working Group (IWG) Criteria. CR is defined as the disappearance of all evidence of disease and PR is defined as regression of measurable disease and no new sites (as specified in the Cheson 2007, IWG response criteria).
Response rate: partial plus complete [ Time Frame: CT scans of neck, chest, abdomen, pelvis, and PET scan are performed during screening and repeated, up to 12 months. Bone marrow aspiration and biopsy are performed during screening and to confirm CR if appropriate. ]
Complete list of historical versions of study NCT00807495 on ClinicalTrials.gov Archive Site
  • Time to Progression (TTP) [ Time Frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years) ]
    Time to progression (TTP) is defined as the time in days from the date of first study drug administration to the date of first documentation of Progressive Disease (PD) according to IWG criteria (Cheson 2007). PD is defined as any new lesion or increase by >50% of previously involved sites from nadir.
  • Progression Free Survival (PFS) [ Time Frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years) ]
    PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death.
  • Duration of Response (DOR) [ Time Frame: Baseline and every 2 cycles up to Month 12, from Cycle 16 every 4 cycles until disease progression, after end of treatment every 12 weeks for up to 12 Months (Up to 4 years) ]
    DOR is defined as the time from the date of first documentation of a CR, or partial response (PR) to the date of first documentation of PD according to IWG criteria. CR definition includes the complete disappearance of all evidence of disease, the definition of PR includes at least a 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses, and PD is defined as any new lesion or increase by >50% of previously involved sites from nadir, as described in the IWG response criteria (Cheson 2007).
  • Number of Participants With Treatment-Emergent Adverse Events [ Time Frame: First dose of study drug to 30 days after last dose (Up to 25 months) ]
    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and includes all-causality (ie, treatment-related and not treatment-related as assessed by the investigator).
  • Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events [ Time Frame: First dose of study drug to 30 days after last dose (Up to 25 months) ]
    Vital signs (blood pressure, heart rate, and oral temperature) measurements were obtained throughout the study. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
  • Number of Participants With Abnormal Laboratory Values Reported as Treatment-Emergent Adverse Events [ Time Frame: First dose of study drug to 30 days after last dose (Up to 25 months) ]
    Abnormal laboratory values for chemistry or hematology tests that were assessed by the investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE V4). A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.
  • Time to progression, progression free survival, and duration of response. [ Time Frame: Imaging performed serially to 12 months. Bone marrow performed during screening and repeated to confirm complete response if appropriate. ]
  • Safety, tolerability based on vital signs, physical examination, laboratory tests, adverse events [ Time Frame: Through 30 days after last dose. ]
Not Provided
Not Provided
 
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Aggressive Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the anti-tumor activity of alisertib (MLN8237) in participants with relapsed or refractory non-hodgkin's lymphoma.

The drug being tested in this study is called alisertib (MLN8237). Alisertib is being tested to treat people who have relapsed or refractory non-Hodgkin's lymphoma (NHL). The study looked at anti-tumor activity in participants who received alisertib.

The study enrolled 48 patients. Participants were categorized as per disease subtypes into five subtypes: Large B-Cell lymphoma, mantle cell lymphoma, transformed follicular lymphoma, Burkitts lymphoma and aggressive T-Cell lymphoma (Note: There were no participants enrolled with Precursor B-lymphoblastic Leukemia/Lymphoma). Participants received:

• Alisertib 50 mg BID on Days 1 to 7

All participants took alisertib capsules approximately every 12 hours each day for 7 days followed by a 14-day rest period in a 21-days cycle. MLN8237 was supplied in capsules of 5 or 25 mg strength.

This multi-center trial was conducted in United States. The overall time to participate in this study was until there is evidence of disease progression or unacceptable treatment-related toxicity. If the participant would derive benefit from continued alisertib treatment beyond 24 months, the Sponsor was consulted for approval of further treatment. Participants made multiple visits to the clinic, with imaging assessments every 12 weeks. Participants discontinuing treatment prior to disease progression continue with clinic visits, chemistry and hematology lab testing, and tumor assessments every 12 weeks up to 12 months after last dose of study drug for follow-up assessments.

Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Diffuse Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Burkitt's Lymphoma
  • T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma
  • Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component
Drug: Alisertib
Alisertib capsules
Other Name: MLN8237
Experimental: Alisertib 50 mg
Alisertib 50 mg, capsules, orally, twice daily for 7 days, followed by 14-day washout period in 21-day cycles until disease progression or unacceptable treatment-related toxicity (Up to 24 months or longer with Sponsor approval).
Intervention: Drug: Alisertib
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007 Feb 10;25(5):579-86. Epub 2007 Jan 22.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
41
February 13, 2013
January 4, 2011   (Final data collection date for primary outcome measure)

Each participant must meet all of the following inclusion criteria to be enrolled in the study:

  1. Participant must have histological or cytological diagnosis of a hematological malignancy of the following types that has relapsed or was refractory to prior therapy:

    • Diffuse large B-cell lymphoma
    • Mantle cell lymphoma
    • Burkitt's lymphoma
    • Precursor B-lymphoblastic leukemia/lymphoma
    • T-cell lymphoma, excluding primary cutaneous T-cell lymphoma
    • Transformed follicular lymphoma with ≥ 50% diffuse large cell component.
  2. Male or female participants 18 years or older.
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
  4. Measurable disease.

Exclusion criteria include the following:

  1. Pregnant or lactating females.
  2. Known human immunodeficiency virus (HIV) positive or AIDS-related illness.
  3. Any serious medical or psychiatric illness that could interfere with the completion of treatment.
  4. Total bilirubin ≥ 1.5 × the upper limit of normal (ULN).
  5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥ 2.5 × the ULN. AST, ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to their underlying hematological disorder.
  6. Absolute neutrophil count (ANC) < 1,250/mm^3.
  7. Platelet count < 75,000/mm^3.
  8. Calculated creatinine clearance < 30 mL/minute.
  9. Autologous stem cell transplant less than 6 months prior to enrollment.
  10. Participants who have undergone allogeneic stem cell or organ transplantation.
  11. Systemic antineoplastic therapy including glucocorticoids (> 15 mg prednisone/day or equivalent), or treatment with an investigational agent within 14 days preceding the first dose of study drug treatment.
  12. Participants who have received treatment with nitrosoureas, mitomycin C, rituximab, alemtuzumab, or other unconjugated antibody treatment, within 12 weeks prior to first dose.
  13. Participants who have received treatment with radioimmunoconjugates or within 12 weeks prior to first dose.
  14. Participants who have received radiotherapy within 21 days prior to first dose.
  15. Myocardial infarction within 6 months of enrollment or current history of New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
  16. Major surgery within 14 days prior to the first dose.
  17. Infection requiring systemic antibiotic therapy within 14 days prior to the first dose or other serious infection.
  18. Clinically uncontrolled central nervous system (CNS) involvement.
  19. Inability to swallow capsules.
  20. History of uncontrolled sleep apnoea syndrome and other conditions that could result in excessive daytime sleepiness (eg, Chronic obstructive pulmonary disease - COPD).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00807495
C14004
U1111-1187-1268 ( Registry Identifier: WHO )
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Takeda ( Millennium Pharmaceuticals, Inc. )
Millennium Pharmaceuticals, Inc.
Not Provided
Study Director: Medical Director Clinical Science Millennium Pharmaceuticals, Inc.
Takeda
February 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP